Sectors

CRNX
Crinetics Pharmaceuticals, Inc.
84.95
10 x 84.92
3 x 85.03
bid
ask
+
0.11
0.13%
7 @ 06:42 PM
84.97 +0.02 (0.02%)
Ytd82.49%
1y174.12%
84.92
day range
85.01
31.00
52 week range
85.01
Open84.96Prev Close84.84Low84.92High85.01Mkt Cap9.01B
Vol8.18MAvg Vol3.98MEPS-5.05P/EN/AForward P/E-21.00
Beta0.09Short Ratio2.26Inst. Own120.02%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-0550-d Avg73.85200-d Avg50.231yr Est85.50
Income Statement
Total Revenue25.12M
Revenues (USD)25.12M
Cost of Revenue154.00K
Gross Profit24.96M
Operating Expenses157.42M
Research and Development Expense99.85M
Selling, General and Administrative Expense57.57M
Operating Income-132.46M
Net Income-120.85M
Net Income Common Stock-120.85M
Net Income Common Stock (USD)-120.85M
Consolidated Income-120.85M
Earnings per Basic Share-1.14
Earnings per Basic Share (USD)-1.14
Earnings per Diluted Share-1.14
Earning Before Interest & Taxes (EBIT)-120.85M
Earning Before Interest & Taxes (USD)-120.85M
Weighted Average Shares105.56M
Weighted Average Shares Diluted105.56M
Balance Sheet
Cash and Equivalents55.50M
Cash and Equivalents (USD)55.50M
Investments1.15B
Investments Current1.15B
Investments Non-Current800.00K
Trade and Non-Trade Receivables11.96M
Current Assets1.24B
Property, Plant & Equipment Net52.18M
Total Assets1.32B
Debt Current6.59M
Total Debt47.19M
Current Liabilities79.92M
Debt Non-Current40.61M
Total Liabilities129.92M
Accumulated Retained Earnings (Deficit)-1.67B
Accumulated Other Comprehensive Income-3.01M
Shareholders Equity1.19B
Shareholders Equity (USD)1.19B
Assets Non-Current77.52M
Total Debt (USD)47.19M
Deferred Revenue5.13M
Inventory3.49M
Liabilities Non-Current50.01M
Trade and Non-Trade Payables42.44M
Cash Flow
Depreciation, Amortization & Accretion1.76M
Net Cash Flow from Financing8.93M
Net Cash Flow / Change in Cash & Cash Equivalents-58.97M
Capital Expenditure-521.00K
Issuance (Purchase) of Equity Shares8.93M
Net Cash Flow from Investing26.29M
Net Cash Flow - Investment Acquisitions and Disposals26.81M
Net Cash Flow from Operations-94.19M
Share Based Compensation24.88M